Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-17
2008-06-17
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C514S266210, C514S267000, C544S251000, C544S293000
Reexamination Certificate
active
07388014
ABSTRACT:
Quinazoline derivatives represented by the general formulapharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperproliferative disorders are also described.
REFERENCES:
patent: 5296484 (1994-03-01), Coghlan et al.
patent: 5457105 (1995-10-01), Baker
patent: 5480883 (1996-01-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 6046206 (2000-04-01), Pamukcu et al.
patent: 6057326 (2000-05-01), Brasca et al.
patent: 6127541 (2000-10-01), Onoda et al.
patent: 6258820 (2001-07-01), Uckun et al.
patent: 6645969 (2003-11-01), Myers et al.
patent: 2002/0137757 (2002-09-01), Uckun et al.
patent: 2003/0191308 (2003-10-01), Hennequin et al.
patent: 0 566 226 (1993-10-01), None
patent: 0 635 507 (1995-01-01), None
patent: WO 95/19970 (1995-07-01), None
patent: 96-29331 (1996-09-01), None
patent: WO 96/29331 (1996-09-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 96/33978 (1996-10-01), None
patent: WO 97/30034 (1997-08-01), None
patent: WO 97/49688 (1997-12-01), None
U.S. Appl. No. 08/620,719, filed Mar. 1996, Himmelsbach et al.
Philip Skehan et al., New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, Articles, pp. 1107-1112, vol. 82, No. 13, Jul. 4, 1990.
Alexander J. Bridges et al., Tyrosine Kinase Inhibitors 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6, 7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor, Journal of Medicinal Chemistry, 1996, vol. 39, No. 1, pp. 267-276, 1996.
Gordon W. Rewcastle et al., Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor, Journal of Medicinal Chemistry, 1996, vol. 39, No. 4, pp. 918-928, 1996.
Brian J. Palmer et al., Tyrosine Kinase Inhibitors. 11. Soluble Analogues of Pyrrolo- and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation and Modeling of the Mode of Binding, Journal of Medicinal Chemistry, 1997, vol. 40, No. 10, pp. 1519-1529, 1997.
Jeff B. Smaill et al., Tyrosine Kinase Inhibitors 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino) quinazoline- and 4-(Phenylamino) pyrido [3,2-d] pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions, Journal of Medicinal Chemistry, 2000, vol. 43, No. 7, pp. 1380-1397, 2000.
HOU Chemical Abstracts AN 138:117246 (2003).
Denny Chemical Abstract AN 135:313144 (2001).
Denny Chemical Abstract AN 125:25623 (1996).
Bridges Chemical Abstract AN 124:134940 (1995) (Equivalent to C35).
Rewcastle Chemical Abstract AN 125:256632 (1995).
Bigar Chemical Abstract AN 76:34199 (1970).
Lutz Chemical Abstract AN 71:30492 (1968).
Biniecki Chemical Abstract AN 57:83258 (1961).
Szczepankiewicz Chemical Abstract AN 134:147558 (2000).
Szczepankiewicz Chemical Abstract AN 128:244010 (1998).
IFE Chemical Abstract AN 123:285897 (1995).
Gour Chemical Abstract AN 140:87658 (2004).
Gour Chemical Abstract AN 137:363033 (2002).
Gour Chemical Abstract AN 135:147398 (2001).
Grigis Chemical Abstract AN 107:198230 (1986) (Equivalent to C36).
Sun Chemical Abstract AN 97:122727 (1981).
Tobe Chemical Abstract AN 139:46390 (2003).
Calestani Chemical Abstract AN:135:37101 (2001).
Gazit Chemical Abstract AN 125-264991 (1996).
Wakelking Chemical Abstract AN 124:249673 (1996).
Barker Chemical Abstract AN 118:191758 (1992).
Johannsen Chemical Abstract AN 110:75427 (1987).
Csuros Chemical Abstract AN 76:153706 (1972).
Blenke Chemical Abstract AN 139:94784 (2003).
Wright Chemical Abstract AN 134:202418 (2000).
Showalter Chemical Abstract AN 132:87758 (1999).
Bridges Chemical Abstract AN 127:35871 (1997).
Himmelsbach Chemical Abstract AN 126:8131 (1996).
Himmelsbach Chemical Abstract AN 125:275902 (1996).
Alexander J. Bridges, Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by 4-α Phenethylamino) quinazolines, Bioorganic & Medicinal Chemistry, vol. 3 No. 12, pp. 1651-1656, 1995.
Nabih S. Girgis [2], Phosphorus Pentoxide in Organic Synthesis 25, Chemica Scripta 1986, 26, 617-621, Department of Chemistry, Odense University, Campusuej 55, DK-5230 Odense M. Denmark, Received Oct. 24, 1985; accepted Feb. 5, 1986.
Ahn Chang H.
Lee Young B.
Gollin Michael A.
Haddaway Keith G.
Rexahn Pharmaceuticals, Inc.
Truong Tamthom N
Venable LLP
LandOfFree
Quinazoline derivatives and therapeutic use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline derivatives and therapeutic use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives and therapeutic use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2808953